GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (MEX:NVS N) » Definitions » Cyclically Adjusted FCF per Share

Novartis AG (MEX:NVS N) Cyclically Adjusted FCF per Share : MXN112.85 (As of Mar. 2025)


View and export this data going back to 2008. Start your Free Trial

What is Novartis AG Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Novartis AG's adjusted free cash flow per share for the three months ended in Mar. 2025 was MXN22.236. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is MXN112.85 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Novartis AG's average Cyclically Adjusted FCF Growth Rate was 4.70% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 4.40% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 3.20% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 2.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Novartis AG was 4.40% per year. The lowest was 0.50% per year. And the median was 1.70% per year.

As of today (2025-06-29), Novartis AG's current stock price is MXN2092.19. Novartis AG's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was MXN112.85. Novartis AG's Cyclically Adjusted Price-to-FCF of today is 18.54.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Novartis AG was 21.78. The lowest was 15.04. And the median was 18.11.


Novartis AG Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Novartis AG's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG Cyclically Adjusted FCF per Share Chart

Novartis AG Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 88.97 94.19 94.82 96.34 107.39

Novartis AG Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 86.76 93.16 107.72 107.39 112.85

Competitive Comparison of Novartis AG's Cyclically Adjusted FCF per Share

For the Drug Manufacturers - General subindustry, Novartis AG's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis AG's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Novartis AG's Cyclically Adjusted Price-to-FCF falls into.


;
;

Novartis AG Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novartis AG's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=22.236/107.7224*107.7224
=22.236

Current CPI (Mar. 2025) = 107.7224.

Novartis AG Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 11.958 100.464 12.822
201509 16.260 99.785 17.553
201512 22.659 99.386 24.560
201603 5.980 99.475 6.476
201606 18.763 100.088 20.194
201609 18.603 99.604 20.119
201612 24.200 99.380 26.232
201703 11.751 100.040 12.653
201706 23.073 100.285 24.784
201709 22.441 100.254 24.113
201712 24.060 100.213 25.863
201803 14.243 100.836 15.216
201806 28.972 101.435 30.768
201809 25.673 101.246 27.315
201812 26.135 100.906 27.900
201903 14.870 101.571 15.771
201906 21.992 102.044 23.216
201909 34.353 101.396 36.496
201912 23.741 101.063 25.305
202003 20.921 101.048 22.303
202006 35.154 100.743 37.589
202009 24.269 100.585 25.991
202012 25.971 100.241 27.909
202103 11.479 100.800 12.267
202106 31.164 101.352 33.123
202109 40.011 101.533 42.450
202112 30.194 101.776 31.958
202203 7.032 103.205 7.340
202206 28.862 104.783 29.672
202209 39.206 104.835 40.286
202212 32.641 104.666 33.594
202303 21.834 106.245 22.138
202306 21.915 106.576 22.151
202309 39.413 106.570 39.839
202312 14.437 106.461 14.608
202403 8.952 107.355 8.983
202406 37.133 107.991 37.041
202409 53.301 107.468 53.427
202412 31.803 107.128 31.979
202503 22.236 107.722 22.236

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Novartis AG  (MEX:NVS N) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Novartis AG's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=2092.19/112.85
=18.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Novartis AG was 21.78. The lowest was 15.04. And the median was 18.11.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Novartis AG Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Novartis AG's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Novartis AG Business Description

Industry
Address
Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.

Novartis AG Headlines

No Headlines